Treatment Outcome of Locally Advanced Non-small Cell Lung Cancer.
- Author:
Heui Kwan LEE
1
;
Hyoung Cheol KWON
;
Sun Young LEE
;
Jung Soo KIM
Author Information
1. Department of Radiation Oncology, Chonbuk National University Hospital, Jeonju, Korea. hckwon@chonbuk.ac.kr
- Publication Type:Original Article
- Keywords:
Non-small cell lung carcinoma;
Radiotherapy;
Survival
- MeSH:
Carcinoma, Non-Small-Cell Lung*;
Chemoradiotherapy;
Drug Therapy;
Humans;
Radiotherapy;
Retrospective Studies;
Survival Rate;
Treatment Outcome*
- From:The Journal of the Korean Society for Therapeutic Radiology and Oncology
2006;24(4):237-242
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
PURPOSE: We evaluated retrospectively the outcome of locally advanced non-small cell lung cancer patients treated with definitive radiotherapy to find out prognostic factros affecting survival. MATERIALS AND METHODS: 216 cases of stage IIIB non-small cell lung cancer were with treated radiotherapy at our Hospital between 1991 to 2002 and reviewed retrospectively. Cases were classified by mode of treatment and response to treatment. Patients showing complete response or partial response to treatment were included in the "response group", while those showing stable or progressive cancer were included in the "non-response group". RESULTS: 30 patients completed the planned radiotherapy treatments and 39 patients completed combined treatments or chemoradiotherapy. Median survival was 4.6 months for patients treated with radiotherapy and 9.9 months for those undergoing combined radiotherapy and chemotherapy. Survival rates for the first year were 13.3% with radiotherapy and 35.9% with chemoradiotherapy. In the second year, 3.3% of the radiotherapy patients survived and 20.5% of the patients receiving chemoradiotherapy survived. By the third year, 15.4% of the patients receiving the combined treatments survived. None of the patients treated with radiotherapy alone lived to the third year, however. Overall survival was significantly different between the radiotherapy patients and the combined chemoradiotherapy patients (p<0.001). In the response group, median survival was 7.2 months with radiotherapy and 16.5 months with combined therapy. In the non-response group, median survival was 4.4 months with radiotherapy and 6.7 months with combined treatments. Severe acute complications (grade 3) occurred in 2 cases using radiotherapy, and in 7 cases using combined therapy. CONCLUSION: When the patients with stage IIIB non-small cell lung cancer received chemoradiotherapy, treatment response rate and overall survival was greater than with radiation alone.
